Table 5.
Andersen-Gill regression model with the endpoint OS analysed on an intention-to-treat basis
| HR | 95 % CI | p value | |
|---|---|---|---|
| Genetic risk according to ELN | |||
| Favorable risk | 0.45 | 0.34–0.58 | <0.0001 |
| Intermediate-2 | 1.03 | 0.80–1.32 | 0.84 |
| Adverse risk | 1.87 | 1.50–2.34 | <0.0001 |
| s/t-AML | 1.32 | 1.04–1.67 | 0.021 |
| Gender (male) | 1.22 | 1.03–1.44 | 0.024 |
| Age (diff. 10 years) | 1.23 | 1.13–1.34 | <0.0001 |
| WBC (median-dichotomized)* | 1.55 | 1.30–1.85 | <0.0001 |
| Valproic acid | 1.36 | 1.10–1.67 | 0.004 |
| Allogeneic HCT in 1st CR | 0.71 | 0.58–0.87 | 0.001 |
| ATRA | 0.89 | 0.76–1.06 | 0.19 |
Variables excluded after limited backward selection in the order of their exclusion: DNMT3A mutational status (p = 0.95), FLT3-TKD (p = 0.85), ASXL1 mutational status (p = 0.70), RUNX1 mutational status (p = 0.52), IDH1 mutational status (p = 0.29) and IDH2 mutational status (p = 0.13)
*The median WBC of the whole cohort was 12.7 G/L reference group intermediate-1